Insights On CONTRACT PHARMA MANUFACTURING

  1. Beyond Sensitivity: Lessons From Developing A Robust Multi-Matrix qPCR Assay For AAV Vector Shedding 8/17/2026

    AAV gene therapy shedding assays demand matrix-specific extraction and rigorous validation across blood, semen, urine, and saliva. Learn the strategies that ensure reliable qPCR data across biological matrices.

  2. Navigating An Uncertain Regulatory Environment For mRNA-Based Products 8/17/2026

    mRNA developers face a regulatory gap: as of 2024, neither FDA nor EMA has issued CMC-specific guidelines. Learn how early regulator engagement and CDMO partnerships reduce risk.

  3. Exploring 4 Patient-Centric Trends Shaping Today's Biopharma Landscape 8/17/2026

    Patient centricity is reshaping pharma drug development through supply chain resiliency, decentralized trials, and patient-friendly formulations. Learn what these shifts mean for your pipeline strategy.

  4. Ophthalmic Drug Delivery: Meeting Modern Challenges With A Next Generation Solution 8/17/2026

    Ophthalmic injectable packaging demands early strategic attention. Learn how silicone oil contamination, particulate limits, and dosing accuracy challenges can derail development programs and what it takes to stay compliant.

  5. Comprehensive Guide: Managing Nitrosamine Risk And NDSRIs 8/17/2026

    Manage nitrosamines proactively by addressing drug substance impurities and excipient nitrite variability through product-specific testing and raw material screening.

  6. Cracking Complexity: Leveraging Lessons Learned For Future Bispecific Development 8/14/2026

    The shift from static platforms to adaptive, knowledge-driven development helps biopharma teams manage BsAb complexity, accelerate analytical, purification, and formulation development, and improve IND readiness.

  7. The Impact Of hcDNA Analytics On Bioprocess Performance 8/14/2026

    Reliable hcDNA monitoring can improve bioprocess performance, support compliance, and guide upstream and downstream decisions that impact quality and yield.

  8. Strengthening cIEF Method Validation With cIEF-MS 8/14/2026

    Preparing for method validation, a biopharma company needed to characterize cIEF charge variants and confirm peak identities for regulatory readiness.

  9. Confirming Structural Consistency With HDX-MS 8/14/2026

    To support regulatory confidence, a biopharma company evaluated whether manufacturing changes affected its monoclonal antibody's higher-order structure.

  10. Confident Sialic Acid Identification With MS/MS 8/14/2026

    Traditional mass spectrometry left uncertainty around potentially immunogenic glycans. Learn how a biologics developer achieved regulatory-ready clarity.